Bicycle Therapeutics Q3 EPS $(1.26) Misses $(1.17) Estimate, Sales $5.35M Miss $13.09M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bicycle Therapeutics (NASDAQ:BCYC) reported Q3 losses of $(1.26) per share, missing the analyst consensus estimate of $(1.17) by 7.69%. This is a 31.25% decrease over losses from the same period last year. The company also reported quarterly sales of $5.35M, missing the analyst consensus estimate of $13.09M by 59.11%. This is a 76.05% increase over sales from the same period last year.
November 02, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Bicycle Therapeutics reported Q3 losses and sales that missed analyst estimates. This could negatively impact the company's stock in the short term.
Bicycle Therapeutics reported lower than expected earnings and sales for Q3. This underperformance is likely to negatively impact investor sentiment and could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100